EFMC-ISMC 2021

XXVI EFMC International Symposium on Medicinal Chemistry

 Virtual Event    August 29-September 2, 2021

Programme

Indicated times are in CEST timezone.



10:00

Start of sessions

EFMC-ISMC 2021 Opening
Morning Session
EFMC-ISMC 2021 Opening
Morning Session
EFMC-ISMC 2021 Opening Ceremony

10:00
Opening Address by EFMC-ISMC 2021 Chairman
Prof. Karl-Heinz ALTMANN
ETH ZÜRICH, Zürich, Switzerland
Address by EFMC president
Prof. Rui MOREIRA
UNIVERSITY OF LISBON, Lisbon, Portugal
10:15
Opening Lecture
Creating the Next Generation of Therapeutics - Medicinal Chemistry Unleashed (PL001)
Dr Karin BRINER
NOVARTIS, Cambridge, United States

THE NAUTA PHARMACOCHEMISTRY AWARD FOR MEDICINAL CHEMISTRY AND CHEMICAL BIOLOGY
Award Ceremony
10:55
Award Ceremony presided by EFMC Past-President
Dr Yves P. AUBERSON
NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland
Nauta Award Presentation
Prof. Henk TIMMERMAN
VU UNIVERSITY AMSTERDAM, Oegstgeest, The Netherlands
Dr Andele NAUTA
PROF. DR. W. TH NAUTA STICHTING, The Netherlands
11:05
The Nauta Pharmacochemistry Award for Medicinal Chemistry and Chemical Biology
Award Lecture
Partial Agonism in the Picture (AL001)
Prof. Ad P. IJZERMAN
LEIDEN UNIVERSITY, Leiden, The Netherlands
11:45
End of Morning Session
13:00

Start of sessions

EFMC-ISMC 2021 Opening
Afternoon Session
EFMC-ISMC 2021 Opening
Afternoon Session
13:00
THE UCB-EHRLICH AWARD FOR EXCELLENCE IN MEDICINAL CHEMISTRY
Award Ceremony
Dr Yves P. AUBERSON
NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland
Dr Adrian HALL
UCB PHARMA S.A., Braine-l'Alleud, Belgium
13:10
The UCB-Ehrlich Award for Excellence in Medicinal Chemistry
Award Lecture
Experiences & Future Direction for Medicinal Chemistry in Cardiovascular, Renal and Metabolism Diseases (AL002)
Dr Malin LEMURELL
ASTRAZENECA, Gothenburg, Sweden
13:50
THE PROUS INSTITUTE-OVERTON AND MEYER AWARD FOR NEW TECHNOLOGIES IN DRUG DISCOVERY
Award Ceremony
Dr Yves P. AUBERSON
NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland
Dr Josep Jr. PROUS
PROUS INSTITUTE FOR BIOMEDICAL RESEARCH, Barcelona, Spain
14:00
The Prous Institute - Overton and Meyer Award for New technologies in Drug Discovery
Award Lecture
De Novo Drug Design with Machine Intelligence (AL003)
Prof. Gisbert SCHNEIDER
ETH ZÜRICH, Zürich, Switzerland
14:40
EFMC Fellows Ceremony
Prof. Rui MOREIRA
UNIVERSITY OF LISBON, Lisbon, Portugal
Dr Yves P. AUBERSON
NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland
15:10
Closing
15:15

End of the Day

09:30

Start of sessions

Plenary Session
Plenary Session
Chair
Dr Karl-Heinz BARINGHAUS
SANOFI, Frankfurt, Germany
09:30
Medicinal Chemistry: More than Ever (PL002)
Dr Jean-Paul CLOZEL
IDORSIA PHARMACEUTICALS LTD, Allschwil, Switzerland
10:15

Start of sessions

Session 1 'Chemical Biology'

Molecular Imaging Tools for Chemical Biology


Session 2 'Technologies'

Novel Strategies and Methods for Drug Discovery and Development
(CPA Session)
Session 3 'Drug Discovery Projects'

Chemical Tools and Drug Discovery for Neuroinflammation
(EuChemS Session)
Session 1 'Chemical Biology'

Molecular Imaging Tools for Chemical Biology


10:15
Session Chair
Dr Valle PALOMO
CENTRO DE INVESTIGACIONES BIOLÓGICAS-CSIC, Madrid, Spain
10:20
Translational Chemical Biology (LE001)
Prof. Gonçalo BERNARDES
UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom
11:00
Chemical Tools to Study Redox Biology (LE002)
Prof. Pablo RIVERA FUENTES
EPF LAUSANNE, Lausanne, Switzerland
11:20
Sensing Enzymatic Activity with Quantum Dots in Patient-Derived Neurodegenerative Disease Models (LE003)
Dr Valle PALOMO
CENTRO DE INVESTIGACIONES BIOLÓGICAS-CSIC, Madrid, Spain
11:40
Pattern-generating Fluorescent Molecular Probes for Chemical Biology (LE004)
Dr Leila MOTIEI
WEIZMANN INSTITUTE OF SCIENCE, Rehovot, Israel
Session 2 'Technologies'

Novel Strategies and Methods for Drug Discovery and Development
(CPA Session)
10:15
Session Chair
Prof. Ke DING
JINAN UNIVERSITY, Guangzhou, China
10:20
Along the Allostery Stream: Recent Advances in Computational Methods for Allosteric Drug Discovery (LE005)
Prof. Jian ZHANG
SHANGHAI JIAO TONG UNIVERSITY, Shanghai, China
11:00
Molecular Glue Design for Targeted Cancer Therapy (LE006)
Dr Xiangbing QI
TSINGHUA UNIVERSITY | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCE, China
11:20
Discovery of New SARS-COV-2 MPRO Inhibitors With Potent in vitro and In vivo Antiviral Activity (LE007)
Prof. Shengyong YANG
SICHUAN UNIVERSITY, Sichuan, China
11:40
Development of A New Target Identification System for Small Molecules in Trypanosoma Brucei Parasites (LE008)
Ms Suzanne Sherihan SAHRAOUI
UNIVERSITY OF GENEVA, Geneva, Switzerland
Session 3 'Drug Discovery Projects'

Chemical Tools and Drug Discovery for Neuroinflammation
(EuChemS Session)
10:15
Session Chair
Dr Sonsoles MARTIN-SANTAMARIA
CIB-CSIC, Madrid, Spain
10:20
Microglia in Neuroinflammation: an Intriguing Target towards Neuroprotection and Neuroregeneration (LE009)
Prof. Barbara MONTI
UNIVERSITY OF BOLOGNA, Bologna, Italy
11:00
Development of Fluorinated PET Tracers for Imaging of α1 Receptors in the Brain (LE010)
Prof. Bernhard WÜNSCH
UNIVERSITY OF MÜNSTER, Münster, Germany
11:20
Boosting the Resolution of Inflammation Through Formyl Peptide Receptor 2 (FPR2) Agonists as a Novel Strategy in Neuroinflammation-associated Central Nervous System Disorders (LE011)
Prof. Enza LACIVITA
UNIVERSITÀ DEGLI STUDI DI BARI, Bari, Italy
11:40
Small Molecule Degradeers Targeting Folding Intermediates: the Prion Protein Case Study (LE012)
Dr Andrea ASTOLFI
UNIVERSITY OF PERUGIA, Perugia, Italy
12:00

End of morning session

12:30

Start of sessions

Company Workshop
Company Workshop
12:30
Company Workshop
Schrödinger
LiveDesign: a Collaborative Environment for Real-world Drug Discovery Workflows
13:15

Poster Session 1, Exhibition & Networking

15:30

Start of sessions

Session 4 'Chemical Biology'

Photochemistry in Drug Discovery: Photopharmacology, Phototoxicity and Synthesis
(ACSMEDI Session)
Session 5 'Technologies'

Cryo-EM as an Emerging Tool for Small-Molecule Drug Discovery


Session 6 'Drug Discovery Projects'

Next Generation Drugs for Heart Failure



Session 4 'Chemical Biology'

Photochemistry in Drug Discovery: Photopharmacology, Phototoxicity and Synthesis
(ACSMEDI Session)
15:30
Session Chairs
Mr Timothy J. HENDERSON
MERCK & CO, Boston, United States
Dr Amjad ALI
MERCK & CO. INC., Kenilworth, United States
15:35
Photopharmacology: Towards Light-Controlled Therapy (LE013)
Dr Wiktor SZYMANSKI
UNIVERSITY OF GRONINGEN, Groningen, The Netherlands
16:15
Mapping Cell-Cell Interactions in Tumor Microenvironment via Photocatalytic Proximity Labeling (LE014)
Dr Niyi FADEYI
MERCK & CO, Cambridge, United States
16:35
Azaaurones as Novel Chemotypes Against Mycobacterium Tuberculosis: SAR ADME Profiling and Photo-Switching Properties (LE015)
Mr André CAMPANICO
I.MED.ULISBOA - FFULISBOA, Lisboa, Portugal
16:55
In vivo Adrenergic Modulation with Photopharmacology (LE016)
Dr Davia PRISCHICH
INSTITUTE FOR BIOENGINEERING OF CATALONIA (IBEC) , Barcelona, Spain
Session 5 'Technologies'

Cryo-EM as an Emerging Tool for Small-Molecule Drug Discovery


15:30
Session Chair
Dr Jean-Paul RENAUD
URANIA THERAPEUTICS, Ostwald, France
15:35
Cryo-EM in GPCR Structure Based Drug Discovery (LE017)
Dr Stacey SOUTHALL
SOSEI HEPTARES, Cambridge, United Kingdom
16:15
Allosteric Regulation of GTP Cyclohydrolase I (LE018)
Dr Herbert NAR
BOEHRINGER INGELHEIM, Biberach, Germany
16:35
The Role of Cryo-EM in Fragment-Based Drug Discovery (LE019)
Dr Judith REEKS
ASTEX PHARMACEUTICALS, Cambridge, United Kingdom
16:55
Structure Based Drug Discovery Targeting Helicobacter Pylori, Using Cryo-EM (LE020)
Dr Eva CUNHA
UNIVERSITY OF OSLO & OSLO UNIVERSITY HOSPITAL, OSLO, Norway
Session 6 'Drug Discovery Projects'

Next Generation Drugs for Heart Failure



15:30
Session Chair
Dr Alleyn T. PLOWRIGHT
WREN THERAPEUTICS LTD, Cambridge, United Kingdom
15:35
Identification of Potent and Long Acting Single-Chain Peptide Mimetics of Human Relaxin-2 for Cardiovascular Diseases (LE021)
Dr Sergio MALLART
SANOFI R&D, CHILLY MAZARIN, France
16:15
MAP4K4 Inhibitors For The Suppression Of Cardiac Muscle Cell Death (LE023)
Dr Gary NEWTON
THE INSTITUTE OF CANCER RESEARCH, London , United Kingdom
16:35
Development of Non-Coding RNA Based Next-Generation Heart Failure Therapeutics (LE024)
Dr Thomas THUM
HANNOVER MEDICAL SCHOOL (MHH), Hannover, Germany
16:55
Discovery of Aficamten (CK-274): A Novel, Small Molecule, Cardiac Myosin Inhibitor for the Potential Treatment of Hypertrophic Cardiomyopathies (HCM) (LE022)
Dr Grace CHUANG
CYTOKINETICS, South San Francisco, United States
17:15

Start of sessions

Session 7.1.

First Time Disclosures (Part I)
Session 7.1.

First Time Disclosures (Part I)
Session Chair
Dr Cornelia ZUMBRUNN
IDORSIA PHARMACEUTICALS LTD., Allschwil, Switzerland
17:15
Design and Preclinical Characterization Program Towards BAY 2433334, an Oral Factor XIa Inhibitor for the Prevention and Treatment of Thromboembolic Disorders (LE025)
Dr Susanne ROEHRIG
BAYER HEALTHCARE, Wuppertal, Germany
17:45
First Time Disclosure of BI 1265162, an ENaC Inhibitor for the Treatment of Cystic Fibrosis (LE026)
Dr Jörg KLEY
BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG, Biberach an der Riss, Germany
18:15
Discovery of the Clinical Candidate AZD4604, a Potent and Selective Janus Kinase 1 Inhibitor, as an Inhaled Treatment for Respiratory Disease (LE027)
Dr Magnus NILSSON
ASTRAZENECA, Mölndal, Sweden
18:45

End of the Day

09:30

Start of sessions

EFMC Prize Ceremony & Lectures 2020
EFMC Prize Ceremony & Lectures 2020
09:30
Prize Ceremony
09:35
The 2020 EFMC Prize for a Young Medicinal Chemist in Industry
Discovery of Potent Selective GABAA Alpha5 Positive Allosteric Modulators (PAMs) for the treatment of neurological disorders (PR001)
Dr Giuseppe CECERE
F. HOFFMANN-LA ROCHE, Basel, Switzerland
09:55
The 2020 EFMC Prize for a Young Medicinal Chemist in Academia
Within Our Control? Illuminating How Ephemeral Electrophiles Rewire Cell Decision-Making Processes (PR002)
Prof. Yimon AYE
EPFL, Lausanne, Switzerland
10:15

Start of sessions

Session 8 'Chemical Biology'

Chemical Probes for Target Discovery and Validation

Session 9 'Technologies'

Innovative Synthesis for Medicinal Chemistry


Session 10 'Drug Discovery Projects'

Addressing Neglected and Emerging Viral Diseases with Small Molecules
(AFMC Session)
Session 8 'Chemical Biology'

Chemical Probes for Target Discovery and Validation

10:15
Session Chair
Prof. Gyorgy KESERU
HUNGARIAN ACADEMY OF SCIENCES, Budapest, Hungary
10:20
Chemical Probes to Explore Cancer Biology and Validate Drug Targets (LE028)
Prof. Paul WORKMAN
INSTITUTE OF CANCER RESEARCH, London, United Kingdom
11:00
Chemical Probes to Study Lipid Signaling (LE029)
Dr Mario VAN DER STELT
LEIDEN UNIVERSITY, Leiden, The Netherlands
11:20
Discovery of MRK-740, a First-in-class, Potent, Selective and Cell Active PRDM9 Chemical Probe (LE030)
Dr Christian FISCHER
MERCK, SHARP & DOHME, Boston, United States
11:40
Quenched Activity-based Probes as New Chemical Tools to Analyse Resistance to Antibiotics (LE031)
Ms Rita FÉLIX
IMED.ULISBOA - INSTITUTO DE INVESTIGAÇÃO DO MEDICAMENTO, Lisboa, Portugal
Session 9 'Technologies'

Innovative Synthesis for Medicinal Chemistry


10:15
Session Chair
Prof. Cristina NEVADO
UNIVERSITY OF ZURICH, Zurich, Switzerland
10:20
Recent Developments in Strategies and Tactics Towards Complex Secondary Metabolites (LE032)
Prof. Erick M. CARREIRA
ETH ZÜRICH, Zürich, Switzerland
11:00
Innovative DNA-based Asymmetric Catalysis (LE033)
Dr Stellios ARSENIYADIS
QUEEN MARY UNIVERSITY OF LONDON, London, United Kingdom
11:20
Scaffold-Assisted Peptide Cyclizations: Towards Protein Mimics (LE034)
Prof. Jan VAN MAARSEVEEN
UNIVERSITY OF AMSTERDAM, Amsterdam, The Netherlands
11:40
Synthesis of New Building Blocks from the Chemical Universe Database GDB (LE035)
Ms Aline CARREL
UNIVERSITY OF BERN, Bern, Switzerland
Session 10 'Drug Discovery Projects'

Addressing Neglected and Emerging Viral Diseases with Small Molecules
(AFMC Session)
10:15
Session Chair
Prof. Esin AKI-YALCIN
ANKARA UNIVERSITY, Ankara, Turkey
10:20
Discovery of a Novel Class of Small Molecule Dengue Virus Inhibitors (LE036)
Dr Tim JONCKERS
JANSSEN, Beerse, Belgium
11:00
Antivirals Against Chikungunya Virus: Analyzing the Current Situation to Identify New Opportunities (LE037)
Prof. Maria-Jesus PÉREZ-PÉREZ
INSTITUTO DE QUÍMICA MÉDICA, Madrid, Spain
11:20
Artificial Intelligence for Emerging and Neglected Diseases Drug Discovery (LE038)
Prof. Carolina H. ANDRADE
FEDERAL UNIVERSITY OF GOIAS , Goiânia, Brazil
11:40
Innovative Dihydroorotate Dehydrogenase Clinical Ready Inhibitors as Pan-Coronavirus Antivirals: Targeting the Unexpected with Innovation (LE039)
Dr Marco LOLLI
UNIVERSITY OF TURIN, Torino, Italy
12:00

End of morning session

12:30

Start of sessions

Company Workshop 1
Company Workshop 2
Company Workshop 1
12:30
Chemical Computing Group: Designing Molecules in the Binding Site
Company Workshop 2
12:30
WuXi AppTec: DEL Screening Technology as an Enabling Tool for Medicinal Chemists
13:15

Poster Session 2, Exhibition & Networking

15:30

Start of sessions

Session 11 'Chemical Biology'

Chemical Approaches to Stem Cell Differentiation
(ICBS Session)
Session 12 'Technologies'

Expanding Chemical Space through AI - Linking Synthesis Prediction and Automation

Session 13 'Drug Discovery Projects'

Breathing Life into Inhaled Drug Discovery: Challenges and Breakthroughs to the Clinic
(ACSMEDI Session)
Session 11 'Chemical Biology'

Chemical Approaches to Stem Cell Differentiation
(ICBS Session)
15:30
Session Chair
Prof. Colin POUTON
MONASH UNIVERSITY, Clayton, Australia
15:35
A Chemical Approach to Controlling Cell Fate (LE040)
Dr Sheng DING
UNIVERSITY OF CALIFORNIA SAN FRANCISCO, San Francisco, United States
16:15
Discovery of Small Molecules to Manipulate Cell Fate in vivo: Towards New Therapies for Degenerative Diseases (LE041)
Prof. Angela RUSSELL
UNIVERSITY OF OXFORD, Oxford, United Kingdom
16:35
Probing Embryonic Mesodermal Differentiation Enables Identification of Small Molecule Bone Morphogenetic Protein Activators (LE042)
Prof. Dennis SCHADE
CHRISTIAN-ALBRECHTS-UNIVERSITY OF KIEL, Kiel, Germany
16:55
Potential of Stem Cell Technology in Discovery of Drugs for Neurodegenerative Diseases (LE043)
Prof. Colin POUTON
MONASH UNIVERSITY, Clayton, Australia
Session 12 'Technologies'

Expanding Chemical Space through AI - Linking Synthesis Prediction and Automation

15:30
Session Chair
Dr Ola ENGKVIST
ASTRAZENECA, Mölndal, Sweden
15:35
AI Assisted and Automated Chemical Synthesis (LE044)
Prof. Klavs F. JENSEN
MASSACHUSETTS INSTITUTE OF TECHNOLOGY, Cambridge, United States
16:15
Universal Synthesis Machines and Chemputation (LE045)
Prof. Leroy CRONIN
UNIVERSITY OF GLASGOW, Glasgow, United Kingdom
16:35
AI in the Lab: Automating Chemical Synthesis. Where Next From Here? (LE046)
Dr Teodoro LAINO
IBM RESEARCH EUROPE, Rueschlikon, Switzerland
16:55
Progress and Limitations in Exploring the Chemical Space with AI (LE047)
Dr Ola ENGKVIST
ASTRAZENECA, Mölndal, Sweden
Session 13 'Drug Discovery Projects'

Breathing Life into Inhaled Drug Discovery: Challenges and Breakthroughs to the Clinic
(ACSMEDI Session)
15:30
Session Chair
Dr Nicole GOODWIN
GSK, King of Prussia, United States
15:35
Inhaled New Modalities in Respiratory Disease: Past, Present, Future (LE048)
Dr Werngard CZECHTIZKY
ASTRAZENECA, Mölndal, Sweden
16:15
Discovery of Novel Inhaled PI3Kd Inhibitor by Lung Retention Optimisation (LE049)
Dr Montse ERRA SOLA
ALMIRALL, S.A., Barcelona, Spain
16:35
Introduction to Preclinical Inhaled Drug Dosing and its Application to Measure the Therapeutic Index of Inhaled Steroids (LE050)
Dr Jonathan PHILLIPS
AMGEN, Newbury Park, United States
16:55
Design and Development of Inhaled Molecules to Target the Pulmonary Vasculature (LE051)
Dr Duncan SHAW
NOVARTIS, Cambridge, United States
17:15

Start of sessions

Session 7.2.

First Time Disclosures (Part II)
Session 7.2.

First Time Disclosures (Part II)
17:15
Session Chair
Dr Antonia F. STEPAN
F. HOFFMANN-LA ROCHE LTD, Basel, Switzerland
17:15
Discovery of an Oral, RO5 Compliant, Interleukin 17a Protein-Protein Interaction Modulator for the Treatment of Psoriasis and other Inflammatory Diseases (LE052)
Mr Kevin DACK
LEO PHARMA, Ballerup, Denmark
17:45
Insights to the Discovery and Design of Ataxia Telangiectasia Mutated (ATM) Kinase inhibitors M3541 and M4076 with Strong Anti-tumor Efficacy in Combination Therapy Approaches (LE053)
Dr Thomas FUCHSS
MERCK KGAA, Darmstadt, Germany
18:15
Discovery of JDQ443 a Structurally Unique, Highly Potent, Selective and Orally Bioavailable KRASG12C Covalent Inhibitor (LE054)
Dr Simona COTESTA
NOVARTIS, Basel, Switzerland
18:45

End of the Day

09:30

Start of sessions

EFMC Prize Ceremony & Lectures 2021
EFMC Prize Ceremony & Lectures 2021
09:30
Prize Ceremony
09:35
The 2021 EFMC Prize for a Young Medicinal Chemist in Industry
Integrin Antagonists for the Treatment of Idiopathic Pulmonary Fibrosis (PR003)
Dr Niall ANDERSON
GLAXOSMITHKLINE, Hertfordshire, United Kingdom
09:55
The 2021 EFMC Prize for a Young Medicinal Chemist in Academia
COVID Moonshot – Crowdsourcing a Covid-19 Cure (PR004)
Dr Nir LONDON
THE WEIZMANN INSTITUTE OF SCIENCE, Rehovot, Israel
10:15

Start of sessions

Session 14 'Chemical Biology'

Carbohydrate Recognition and Drug Design

Session 15 'Technologies'

Application of Artificial Intelligence in Drug Discovery Projects
Session 16 'Drug Discovery Projects'

New Strategies and Agents for Targeting Gram-Negative Pathogens
Session 14 'Chemical Biology'

Carbohydrate Recognition and Drug Design

10:15
Session Chair
Dr Alexander TITZ
HELMHOLTZ INSTITUTE FOR PHARMACEUTICAL SCIENCES, Saarbrücken, Germany
10:20
C-type Lectin Receptors as Drug Targets (LE055)
Dr Christoph RADEMACHER
UNIVERSITY OF VIENNA, Vienna, Austria
11:00
Design, Synthesis, and Development of Lectin Ligand Mimetics (LE056)
Prof. Ulf NILSSON
LUND UNIVERSITY, Lund, Sweden
11:20
Lectins from Pathogens: From Structural Glycobiology to Antiadhesive Strategies (LE057)
Dr Anne IMBERTY
CNRS/CERMAV, Grenoble, France
11:40
Development of Glycomimetic Collectin-11 Antagonists to Reduce Complement-Mediated Ischemia-Reperfusion Injuries (LE058)
Dr Rachel HEVEY
UNIVERSITÄT BASEL, Basel, Switzerland
Session 15 'Technologies'

Application of Artificial Intelligence in Drug Discovery Projects
10:15
Session Chair
Dr Christopher SWAIN
CAMBRIDGE MEDCHEM CONSULTING, Duxford, United Kingdom
10:20
Artificial Intelligence in Chemical Biology and Drug Discovery - Data, Applications, and Illusions (LE059)
Prof. Andreas BENDER
UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom
11:00
Augmenting Drug Hunters with Generative Chemistry Models (LE060)
Dr Nadine SCHNEIDER
NOVARTIS, Basel, Switzerland
11:20
Navigating Chemical Space by Artificial Intelligence (LE061)
Dr Gerhard HESSLER
SANOFI-AVENTIS DEUTSCHLAND, Frankfurt am Main, Germany
11:40
Generative Recurrent Neural Networks (RNN) for de novo Drug Design (LE062)
Dr Pooja DESHMUKH
SAI LIFESCIENCES PVT LIMITED, Hyderabad, India
Session 16 'Drug Discovery Projects'

New Strategies and Agents for Targeting Gram-Negative Pathogens
10:15
Session Chair
Dr Vicky STEADMAN
SAI LIFE SCIENCES LTD, Essex, United Kingdom
10:20
Therapies for Gram-Negative Bacterial Infections: New Approaches and Further Generations of Existing Series (LE063)
Dr Mike DAWSON
MIKE DAWSON ANTIMICROBIAL RESEARCH CONSULTANCY LTD., Stevenage, United Kingdom
11:00
Tethered Macrocyclic Peptides, a Novel Antibiotic Class Targeting Acinetobacter Baumannii (LE064)
Dr Patrizio MATTEI
ROCHE INNOVATION CENTER BASEL, Basel, Switzerland
11:20
Discovery of Submicromolar Inhibitors of the Virulence Factor LASB from Pseudomonas Aeruginosa Using Rational Design (LE065)
Prof. Anna K. H. HIRSCH
HELMHOLTZ INSTITUTE FOR PHARMACEUTICAL RESEARCH SAARLAND, Saarbrücken, Germany
11:40
DOTAM-based Sideromycins to Visualize and Treat MDR Bacterial Pathogens in vivo and in vitro (LE066)
Mr Carsten PEUKERT
HELMHOLTZ CENTRE FOR INFECTION RESEARCH, Braunschweig, Germany
12:00

End of morning sesssion

12:30

Start of sessions

Company Workshops 1
Company Workshops 2
Company Workshops 1
12:30
Charles River: Developing Inhaled Drugs for Respiratory Diseases: A Medicinal Chemistry Perspective
Company Workshops 2
12:30
NovAliX: DNA-Encoded Library Technology: Strengths and Development Opportunities
13:15

Poster Session 3, Exhibition & Networking

15:30

Start of sessions

Session 17 'Chemical Biology'

Small Molecules Targeting RNA Function and Processing
Session 18

Highlights of Medicinal Chemistry

Session 19 'Drug Discovery Projects'

Tissue and Cell Specific Drug Delivery
(EUFEPS Session)
Session 17 'Chemical Biology'

Small Molecules Targeting RNA Function and Processing
15:30
Session Chair
Dr Maria DUCA
UNIVERSITY OF CÔTE D'AZUR, Nice, France
15:35
Targeting RNA With Drug-Like Small Molecules (LE067)
Dr Jennifer PETTER
ARRAKIS THERAPEUTICS, Waltham, United States
16:15
Drugging RNA Modifying Enzymes - METTL3 Inhibitors (LE068)
Dr David HARDICK
STORM THERAPEUTICS LTD, Cambridge, United Kingdom
16:35
Modulating Viral RNAS with Amiloride Small Molecules (LE070)
Prof. Amanda HARGROVE
DUKE UNIVERSITY, Durham, United States
16:55
Splice-Switching Small Molecules as Inducers of Apoptosis (LE069)
Ms Emma CAMPBELL
UNIVERSITY OF STRATHCLYDE, Glasgow, United Kingdom
Session 18

Highlights of Medicinal Chemistry

15:30
Session Chair
Prof. Koen AUGUSTYNS
UNIVERSITY OF ANTWERP, Antwerp, Belgium
15:35
Discovery and Development of a Mkk-4 Inhibitors to Increase Liver Regeneration (LE071)
Prof. Stefan LAUFER
UNIVERSITY OF TÜBINGEN, Tübingen, Germany
15:55
Targeting Oncogenic BRAF Using a Novel Allosteric Site (LE072)
Prof. Evripidis GAVATHIOTIS
ALBERT EINSTEIN COLLEGE OF MEDICINE, New York, United States
16:15
Furan-Oxidation Mediated Technology: from in vitro Analysis of Protein-Protein Interactions to GPCR-Ligand Interactions on Live Cells (LE073)
Dr Laia MIRET CASALS
GHENT UNIVERSITY, Gent, Belgium
16:35
LNP023: Discovery and Synthesis of a First-In-Class, Oral Factor B Inhibitor for Treatment of Rare Renal and Hematological Diseases (LE074)
Dr Stefanie FLOHR
NOVARTIS, Basel, Switzerland
16:55
The IUPAC-Richter Prize Lecture
The Discovery of Relpax® and Nurtec ODT® - Two Different Treatments for Migraine Headaches (PR005)
Dr John E. MACOR
SANOFI, Waltham, United States
Session 19 'Drug Discovery Projects'

Tissue and Cell Specific Drug Delivery
(EUFEPS Session)
15:30
Session Chair
Prof. Sebastien PAPOT
SCT & UNIVERSITY OF POITIERS, Poitiers, France
15:35
Antibody-Drug Conjugates (ADC) and Small Molecule-Drug Conjugates (SMDC): a Comparative Evaluation (LE075)
Prof. Dario NERI
ETH ZÜRICH, Zürich, Switzerland
16:15
Nucleic Acids as Household Medicine: Living in The World of RNA Therapeutics (LE076)
Dr Muthiah MANOHARAN
ALNYLAM PHARMACEUTICALS, Cambridge, United States
16:35
Omics-Based Development of Nanomedicines for Safe and Effective Drug Delivery in Cancer (LE077)
Prof. Erem BILENSOY
HACETTEPE UNIVERSITY, Ankara, Turkey
16:55
Targeting the Specificities of the Tumor Microenvironment for Cancer Therapy and Diagnosis (LE078)
Prof. Sebastien PAPOT
SCT & UNIVERSITY OF POITIERS, Poitiers, France
17:15

Start of sessions

Plenary Session
Plenary Session
17:15
Session chair
Prof. Marko ANDERLUH
UNIVERSITY OF LJUBLJANA, Ljubljana, Slovenia
17:15
Translational Chemistry (PL003)
Prof. Phil BARAN
THE SCRIPPS RESEARCH INSTITUTE, La Jolla, United States
18:00

End of the Day

09:30

Start of sessions

Plenary Session
Plenary Session
Chair
Dr Luc VAN HIJFTE
SYMERES, Nijmegen, The Netherlands
09:30
Targeting Protein Scaffolding Function in Kinases (PL004)
Prof. Stefan KNAPP
GOETHE UNIVERSITY FRANKFURT, Frankfurt am Main, Germany
10:15

Start of sessions

Session 20

Emerging Topics

Session 21 'Technologies'

Prodrug Strategies in Drug Design and Discovery
Session 22 'Drug Discovery Projects'

Targeting Fibrotic Diseases with Small Molecules
Session 20

Emerging Topics

10:15
Session Chair
Prof. Beatriz DE PASCUAL-TERESA
CEU SAN PABLO UNIVERSITY, Madrid, Spain
10:20
Toward a New Therapy for Immune-mediated Tissue Injury (LE079)
Dr Julie SPICER
THE UNIVERSITY OF AUCKLAND, Auckland, New Zealand
10:40
A Phenotypic Screen Identifies a Small Molecule that Induces Differentiation of AML Cells in vitro and Shows Anti-Tumour Effects in vivo (LE080)
Dr Laia JOSA CULLERE
INSTITUTE FOR ADVANCED CHEMISTRY OF CATALONIA (IQAC-CSIC), Barcelona, Spain
11:00
Isoform-selective TAU Tubuline Kinase 1 Inhibitors Reduce TDP-43 Hyperphosphorylation: a New Hope in the Treatment of TDP-43 Proteinopathies (LE081)
Ms Vanesa NOZAL GARCIA
CIB - CSIC, Madrid, Spain
11:20
Target-Templated de novo Design of Drug-like Cyclic Peptides: PD-1/PD-L1 Inhibitors (LE082)
Mr Salvador GUARDIOLA
ONA THERAPEUTICS, Barcelona, Spain
11:40
Discovery of LAS200019, a Novel Topical Jak Inhibitor for the Treatment of Inflammatory Skin Diseases (LE083)
Dr Elena GOMEZ
ALMIRALL, BARCELONA, Spain
Session 21 'Technologies'

Prodrug Strategies in Drug Design and Discovery
10:15
Session Chairs
Prof. Bernd CLEMENT
UNIVERSITY OF KIEL, Kiel, Germany
Prof. Jarkko RAUTIO
UNIVERSITY OF EASTERN FINLAND, Kuopio, Finland
10:20
Prodrug Strategies in Medicinal Chemistry (LE084)
Prof. Jarkko RAUTIO
UNIVERSITY OF EASTERN FINLAND, Kuopio, Finland
11:00
New Examples for N-Hydroxyamidine Prodrugs (LE085)
Prof. Bernd CLEMENT
UNIVERSITY OF KIEL, Kiel, Germany
11:20
Neladenoson Bialanate Hydrochloride: a Prodrug Exploration of a Partial Adenosine A1 Agonist (LE086)
Dr Daniel MEIBOM
BAYER PHARMA, Wuppertal, Germany
11:40
Targeted (Pro)Drugs for Improved Treatment of Brain Tumors (LE087)
Dr Kristiina HUTTUNEN
UNIVERSITY OF EASTERN FINLAND, Kuopio, Finland
Session 22 'Drug Discovery Projects'

Targeting Fibrotic Diseases with Small Molecules
10:15
Session Chair
Dr Christian KUTTRUFF
BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG, Biberach, Germany
10:20
Novel Molecular Targets for the Treatment of Fibrosis (LE088)
Prof. Joerg DISTLER
UNIVERSITY OF ERLANGEN–NUREMBERG, Erlangen, Germany
11:00
Discovery of GLPG1205, a First in Class GPR84 Antagonist in Phase II Clinical Trial (LE089)
Dr Romain GOSMINI
GALAPAGOS, Romainville, France
11:20
Investigating the Chameleonic Properties of RGD Integrin Antagonists for the Treatment of Idiopathic Pulmonary Fibrosis (LE090)
Dr James THOMPSON
GLAXOSMITHKLINE, Stevenage, United Kingdom
11:40
Discovery of the Highly Potent and Selective S1P2 Antagonist GLPG2938, a Preclinical Candidate for the Treatment of Idiopathic Pulmonary Fibrosis (LE091)
Dr Adeline PALISSE
GALAPAGOS NV, Mechelen, Belgium
12:00

End of morning session

13:15

Poster Session 4, Exhibition & Networking

15:30

Start of sessions

Session 23 'Chemical Biology'

Target Deconvolution Strategies in Drug Discovery
Session 24 'Technologies'

Biocatalysis & Late Stage Functionalisation

Session 25 'Drug Discovery Projects'

Recent Advances in Anticancer Drug Discovery
Session 23 'Chemical Biology'

Target Deconvolution Strategies in Drug Discovery
15:30
Session Chair
Prof. Paul BRENNAN
UNIVERSITY OF OXFORD, Oxford, United Kingdom
15:35
Mechanistic Insights of a CDK9 Inhibitor via Orthogonal Proteomics Methods (LE092)
Dr Paola CASTALDI
LIFEMINE THERAPEUTICS, Cambridge, United States
16:15
Proteomes in 3D (LE093)
Prof. Paola PICOTTI
ETH ZÜRICH, Zürich, Switzerland
16:35
A Novel Bacterial Three-Hybrid System for Target Identification in Bacteria (LE094)
Ms Radhia EL PHIL
UNIGE, Geneva , Switzerland
16:55
EFMC-YMCS Presentation Prize
Design and Synthesis of Chemical Tools to Probe the Function of TRIM33 (LE095)
Ms Jessica REYNOLDS
UNIVERSITY OF OXFORD, Oxford, United Kingdom
Session 24 'Technologies'

Biocatalysis & Late Stage Functionalisation

15:30
Session Chair
Dr Radka SNAJDROVA
NOVARTIS PHARMA AG, Basel, Switzerland
15:35
Reprogramming Nonribosomal Peptide Biosynthesis (LE096)
Prof. Donald HILVERT
ETH ZURICH, ZURICH, Switzerland
16:15
Flavoenzyme Biocatalysis in Bioorganic and Medicinal Chemistry - Challenges and Opportunities (LE097)
Prof. Marko D. MIHOVILOVIC
TU WIEN, Vienna, Austria
16:35
Utilization of Fe/α-Ketoglutarate-Dependent Enzymes for Stereocontrolled Functionalization (LE098)
Prof. Rebecca BULLER
ZHAW SCHOOL OF LIFE SCIENCES AND FACILITY MANAGEMENT, Wädenswil, Switzerland
16:55
Integration of Biocatalysis into Medicinal Chemistry Programs for Late-Stage Oxidised Derivatives using Polycyps Enzymes (LE099)
Mr Frank SCHEFFLER
HYPHA DISCOVERY LTD, Abingdon, United Kingdom
Session 25 'Drug Discovery Projects'

Recent Advances in Anticancer Drug Discovery
15:30
Session Chair
Prof. Roberto DI SANTO
SAPIENZA UNIVERSITY OF ROME, Rome, Italy
15:35
Targeting Cancer (LE100)
Prof. Daniel RAUH
TU DORTMUND, Dortmund, Germany
16:15
Structure-Based Optimization and Synthesis of M3258, a Potent and Selective Inhibitor of the Immunoproteasome Subunit LMP7 (beta5i) Demonstrating Strong Efficacy in Multiple Myeloma Models (LE101)
Dr Markus KLEIN
MERCK KGAA, Darmstadt, Germany
16:35
Magic in the Moonlight: Our Contribution to the Development of IDO1 Inhibitors for Cancer Immunotherapy (LE102)
Prof. Tracey PIRALI
UNIVERSITÀ DEL PIEMONTE ORIENTALE, Novara, Italy
16:55
Design and Optimization of a First-in-class NACK Inhibitor: A Novel Path to Notch Inhibition (LE103)
Ms Tanya KELLEY
UNIVERSITY OF MIAMI, Miami, United States
17:15

Start of sessions

THE KLAUS GROHE AWARD 2020
Award Ceremony
THE KLAUS GROHE AWARD 2020
Award Ceremony
17:15
Laudatio
Prof. Daniel RAUH
TU DORTMUND, Dortmund, Germany
17:15
Award Ceremony - GDCh President
Prof. Peter R. SCHREINER
JUSTUS-LIEBIG UNIVERSITY, D-35392 Giessen, Germany
17:25
The Klaus Grohe Award Lecture
Chemical-Proteomic Strategies to Fight Multiresistant Bacteria (AL004)
Prof. Stephan A. SIEBER
TECHNICAL UNIVERSITY MUNICH, Garching, Germany
18:05

Start of sessions

EFMC-ISMC Closing Ceremony
EFMC-ISMC Closing Ceremony
18:05
Closing Remarks, Poster Prizes and Welcome to EFMC-ISMC 2022